G. Bradley Cole

General Manager of Precision Oncology

Joined Exact Sciences: 2019

Key Responsibility: Lead the U.S. Oncotype DX business, including sales, marketing, market access, commercial operations and medical affairs.

Previous Employment: Starting in 2004, Brad served as Chief Financial Officer of Genomic Health, leading the company through its initial public offering in 2005 and first full year of profit in 2010. Brad served as the company's Chief Operating Officer from 2009 to 2014 and most recently led the integration for Genomic Health's combination with Exact Sciences. Brad also served in various positions at Guidant Corporation, a designer and developer of cardiovascular medical products. At Guidant, Brad was Vice President, Finance and Business Development, for the Endovascular Solutions Group from 2001 until 2004. Prior to that, he served as Vice President and General Manager of the Vascular Surgery Business Unit of Guidant. Previously, Brad was Vice President and Chief Financial Officer of Applied Biosystems, a publicly traded life sciences company.

Education: MBA, San Jose State University; BS, Biola University

7Asset 1

"Success is defined many times in life as doing something very well and sometimes only one thing. That can be true in business as well, and we have chosen treatment for patients with cancer as a singular focus by which to measure success. In doing so we have the opportunity to do the right thing very well for the benefit of medicine, patients, physicians, payers and the healthcare system overall. Having seen both family members and friends die from cancer in recent years, I can think of no better way to spend my day than helping others who will be faced with similar circumstances in the future.”

Leading the battle against cancer, together.

Exact Sciences and Genomic Health have teamed up to take cancer on, together. By combining our leading portfolio of products, we are continuing our relentless pursuit of earlier detection and smarter answers.

Read the official announcementLearn more About Us